Group 1 - The core point of the article is that Jinhe Biological announced the convening of its 33rd board meeting on October 29, 2025, to review the third-quarter report for 2025 [1] - For the first half of 2025, Jinhe Biological's revenue composition is as follows: veterinary chemical drugs accounted for 61.83%, agricultural product processing accounted for 19.76%, veterinary biological products accounted for 11.12%, environmental protection business accounted for 4.97%, and others accounted for 2.15% [1] - As of the report date, Jinhe Biological has a market capitalization of 5.2 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

Group 1 - The core point of the article is that Jinhe Biological has announced the pledge of shares by its controlling shareholder, Jinhe Holdings, which does not pose any risk to the company's operations or governance [1] - As of the announcement date, Jinhe Holdings has pledged a total of 85.32 million shares, accounting for 38.92% of its holdings, while the total pledged shares by Jinhe Holdings and its concerted parties account for 33.3% of their holdings [1] - Jinhe Biological's revenue composition for the first half of 2025 is as follows: veterinary chemical drugs 61.83%, agricultural product processing 19.76%, veterinary biological products 11.12%, environmental protection business 4.97%, and others 2.15% [1] Group 2 - The current market capitalization of Jinhe Biological is 5.2 billion yuan [1] - The article also highlights the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated $80 billion [1]

Group 1 - The core point of the article is that Jinhe Biology announced the convening of its 32nd meeting of the sixth board of directors, which reviewed the proposal to amend the internal reporting system for significant matters [1] - For the first half of 2025, Jinhe Biology's revenue composition is as follows: veterinary chemical drugs accounted for 61.83%, agricultural product processing accounted for 19.76%, veterinary biological products accounted for 11.12%, environmental protection business accounted for 4.97%, and others accounted for 2.15% [1] - As of the report date, Jinhe Biology has a market capitalization of 5.4 billion yuan [1]

Group 1 - The core point of the article is that Jinhe Biological has announced a stock issuance plan to raise up to 300 million yuan for various projects, including wastewater treatment and product storage [1] - The stock issuance will be directed towards no more than 35 specific investors, with the pricing set at no less than 80% of the average stock price over the previous 20 trading days [1] - The total investment for the wastewater treatment expansion and water resource recycling project is approximately 158 million yuan, with about 136 million yuan expected to be funded from the raised capital [1] Group 2 - Jinhe Biological's revenue composition for the first half of 2025 includes: veterinary chemical drugs at 61.83%, agricultural product processing at 19.76%, veterinary biological products at 11.12%, environmental protection business at 4.97%, and others at 2.15% [1] - As of the report date, Jinhe Biological has a market capitalization of 5.4 billion yuan [2]

Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]

Core Insights - The company Jinhe Biotechnology reported its revenue composition for the first half of 2025, with veterinary chemical drugs accounting for 61.83% of total revenue, followed by agricultural product processing at 19.76%, veterinary biological products at 11.12%, environmental protection business at 4.97%, and others at 2.15% [1] - On August 19, 2025, Jinhe Biotechnology announced the establishment of a wholly-owned subsidiary, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., with an investment of 10 million yuan [3] Revenue Composition - Veterinary chemical drugs: 61.83% [1] - Agricultural product processing: 19.76% [1] - Veterinary biological products: 11.12% [1] - Environmental protection business: 4.97% [1] - Other: 2.15% [1] Corporate Actions - Approval of the establishment of a wholly-owned subsidiary [3] - Investment amount for the new subsidiary: 10 million yuan [3]

Group 1 - The company Jinhe Biology (SZ 002688, closing price: 7.69 yuan) announced on August 12 that it has recently obtained invention and design patent certificates from the National Intellectual Property Administration for a patent titled "Microbial Fermentation Plant with Circumferential Distribution of Tank Body" [2] - For the first half of 2025, Jinhe Biology's revenue composition is as follows: veterinary chemical drugs account for 61.83%, agricultural product processing accounts for 19.76%, veterinary biological products account for 11.12%, environmental protection business accounts for 4.97%, and others account for 2.15% [2]

Group 1 - The core business of the company is the research, production, and sales of veterinary drugs, including veterinary biological products and chemical drugs [1] - The company completed the transfer of 48.4213% equity in Hunan Zhong'an Biological Pharmaceutical Co., Ltd. for a transaction amount of 115 million yuan, and still holds 20% equity after the transfer [1] - On July 30, the company's stock closed at 21.36 yuan, down 0.23% from the previous trading day, with a trading volume of 82,415 hands and a transaction amount of 176 million yuan [1] Group 2 - On July 30, the net outflow of main funds for the company was 10.5372 million yuan [2]

Core Viewpoint - Jinhe Biology announced the convening of its 28th meeting of the 6th Board of Directors on July 30, 2025, to review the full and summary reports of the 2025 semi-annual report [2] Revenue Composition - For the year 2024, the revenue composition of Jinhe Biology is as follows: - Veterinary chemical drugs account for 52.06% - Agricultural product processing accounts for 24.53% - Veterinary biological products account for 14.5% - Environmental protection business accounts for 6.04% - Others account for 2.54% [2]